Thursday, December 14, 2017 9:03:57 PM
Points to ponder:
Delcath added an auditor to the board. <Not something a company going out of business would do.
They eliminated $9.8M long term debt to creditors. <Not something a company going out of business would do.
They still need more cash for continuing operations (burn rate at $1.5M per month) and to bring the product to market. Can they borrow again - take on more debt, or do they issue more class C shares (dilution)? The OS share count I have seen guessed at on this message board has not addressed need for continuing operations funding $.
Being de-listed from NASDAQ to OCTB gives more freedom to Delcath to issue shares regardless of stock price. However, there is little chance of achieving the previous market capitalization of $100+M.
My thoughts are speculation. I enjoy hearing others ideas.
My guess for January is a nice target of .10.
.30 is blue sky and .03 is grey sky.
Volume is going to evaporate starting on Monday 12/18. Most traders going on holiday....
Best wishes, and good luck!
MM
Delcath added an auditor to the board. <Not something a company going out of business would do.
They eliminated $9.8M long term debt to creditors. <Not something a company going out of business would do.
They still need more cash for continuing operations (burn rate at $1.5M per month) and to bring the product to market. Can they borrow again - take on more debt, or do they issue more class C shares (dilution)? The OS share count I have seen guessed at on this message board has not addressed need for continuing operations funding $.
Being de-listed from NASDAQ to OCTB gives more freedom to Delcath to issue shares regardless of stock price. However, there is little chance of achieving the previous market capitalization of $100+M.
My thoughts are speculation. I enjoy hearing others ideas.
My guess for January is a nice target of .10.
.30 is blue sky and .03 is grey sky.
Volume is going to evaporate starting on Monday 12/18. Most traders going on holiday....
Best wishes, and good luck!
MM
Recent DCTH News
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
